AAAAAA
Results: 1-25/28
Authors:
THORNLEY B
ADAMS CE
AWAD AG
Citation: B. Thornley et al., CHLORPROMAZINE VERSUS PLACEBO FOR THE TREATMENT OF SCHIZOPHRENIA - A SYSTEMATIC REVIEW, Schizophrenia research, 29(1-2), 1998, pp. 155-155
Authors:
AWAD AG
LAPIERRE YD
ANGUS C
RYLANDER A
Citation: Ag. Awad et al., NEGATIVE SYMPTOMS AND QUALITY-OF-LIFE IN SCHIZOPHRENIA - RESPONSE TO LOW-DOSE NEUROLEPTIC - LESSONS FROM A CLINICAL-TRIAL, Schizophrenia research, 29(1-2), 1998, pp. 156-156
Authors:
AWAD AG
HESLEGRAVE RJ
VORUGANTI LNP
Citation: Ag. Awad et al., NEUROCOGNITIVE DEFICITS, SYMPTOMS, NEUROLEPTIC SIDE-EFFECTS AND QUALITY-OF-LIFE IN SCHIZOPHRENIA, Schizophrenia research, 29(1-2), 1998, pp. 176-176
Authors:
VORUGANTI LNP
HESLEGRAVE R
AWAD AG
Citation: Lnp. Voruganti et al., RE - CORRELATION BETWEEN COGNITIVE-FUNCTIONING AND THE SYMPTOMATOLOGYOF SCHIZOPHRENIA - THE AUTHORS RESPOND, Canadian journal of psychiatry, 43(8), 1998, pp. 854-855
Authors:
VORUGANTI L
HESLEGRAVE R
AWAD AG
SEEMAN MV
Citation: L. Voruganti et al., QUALITY-OF-LIFE MEASUREMENT IN SCHIZOPHRENIA - RECONCILING THE QUEST FOR SUBJECTIVITY WITH THE QUESTION OF RELIABILITY, Psychological medicine, 28(1), 1998, pp. 165-172
Authors:
AWAD AG
Citation: Ag. Awad, QUALITY-OF-LIFE REDISCOVERED - IMPLICATIONS FOR CLINICAL OUTCOME AND HEALTH ECONOMICS IN SCHIZOPHRENIA, Journal of psychiatry & neuroscience, 22(4), 1997, pp. 229-230
Authors:
HESLEGRAVE RJ
AWAD AG
VORUGANTI LNP
Citation: Rj. Heslegrave et al., THE INFLUENCE OF NEUROCOGNITIVE DEFICITS AND SYMPTOMS ON QUALITY-OF-LIFE IN SCHIZOPHRENIA, Journal of psychiatry & neuroscience, 22(4), 1997, pp. 235-243
Authors:
AWAD AG
LAPIERRE YD
ANGUS C
RYLANDER A
Citation: Ag. Awad et al., QUALITY-OF-LIFE AND RESPONSE OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA TOHALOPERIDOL AND THE ATYPICAL ANTIPSYCHOTIC REMOXIPRIDE, Journal of psychiatry & neuroscience, 22(4), 1997, pp. 244-248
Authors:
VORUGANTI LNP
HESLEGRAVE RJ
AWAD AG
Citation: Lnp. Voruganti et al., QUALITY-OF-LIFE MEASUREMENT DURING ANTIPSYCHOTIC DRUG-THERAPY OF SCHIZOPHRENIA, Journal of psychiatry & neuroscience, 22(4), 1997, pp. 267-274
Authors:
AWAD AG
Citation: Ag. Awad, BIOLOGY OF SCHIZOPHRENIA AND AFFECTIVE DISEASE - WATSON,SJ, Journal of psychiatry & neuroscience, 22(3), 1997, pp. 198-200
Authors:
AWAD AG
VORUGANTI LNP
HESLEGRAVE RJ
Citation: Ag. Awad et al., MEASURING QUALITY-OF-LIFE IN PATIENTS WITH SCHIZOPHRENIA, PharmacoEconomics, 11(1), 1997, pp. 32-47
Authors:
AWAD AG
VORUGANTI LNP
HESLEGRAVE RJ
Citation: Ag. Awad et al., A CONCEPTUAL-MODEL OF QUALITY-OF-LIFE IN SCHIZOPHRENIA - DESCRIPTION AND PRELIMINARY CLINICAL VALIDATION, Quality of life research, 6(1), 1997, pp. 21-26
Authors:
WONG AHC
VORUGANTI LNP
HESLEGRAVE RJ
AWAD AG
Citation: Ahc. Wong et al., NEUROCOGNITIVE DEFICITS AND NEUROLOGICAL SIGNS IN SCHIZOPHRENIA, Schizophrenia research, 23(2), 1997, pp. 139-146
Authors:
VORUGANTI LNP
HESLEGRAVE RJ
AWAD AG
Citation: Lnp. Voruganti et al., NEUROCOGNITIVE CORRELATES OF POSITIVE AND NEGATIVE SYNDROMES IN SCHIZOPHRENIA, Canadian journal of psychiatry, 42(10), 1997, pp. 1066-1071
Authors:
VORUGANTI LNP
HESLEGRAVE RJ
AWAD AG
Citation: Lnp. Voruganti et al., NEUROLEPTIC DYSPHORIA MAY BE THE MISSING LINK BETWEEN SCHIZOPHRENIA AND SUBSTANCE-ABUSE, The Journal of nervous and mental disease, 185(7), 1997, pp. 463-465
Authors:
AWAD AG
Citation: Ag. Awad, PSYCHOPHARMACOLOGY - THE 4TH GENERATION OF PROGRESS - BLOOM,FE, KUPFER,DJ, Journal of psychiatry & neuroscience, 21(5), 1996, pp. 350-351
Authors:
AWAD AG
Citation: Ag. Awad, TEXTBOOK OF PSYCHOPHARMACOLOGY - SCHATZBERG,AF, NEMEROFF,CB, Canadian journal of psychiatry, 41(10), 1996, pp. 657-658
Authors:
AWAD AG
VORUGANTI LNP
HESLEGRAVE RJ
HOGAN TP
Citation: Ag. Awad et al., ASSESSMENT OF THE PATIENTS SUBJECTIVE EXPERIENCE IN ACUTE NEUROLEPTICTREATMENT - IMPLICATIONS FOR COMPLIANCE AND OUTCOME, International clinical psychopharmacology, 11, 1996, pp. 55-59
Authors:
AWAD AG
VORUGANTI LNP
HESLEGRAVE RJ
Citation: Ag. Awad et al., THE AIMS OF ANTIPSYCHOTIC MEDICATION - WHAT ARE THEY AND ARE THEY BEING ACHIEVED, CNS DRUGS, 4(1), 1995, pp. 8-16
Authors:
VORUGANTI LNP
HESLEGRAVE R
AWAD AG
Citation: Lnp. Voruganti et al., NEUROLOGICAL AND NEUROCOGNITIVE CORRELATES OF POSITIVE AND NEGATIVE SCHIZOPHRENIC SYNDROMES, Schizophrenia research, 15(1-2), 1995, pp. 138-139
Authors:
AWAD AG
VORUGANTI LNP
HESLEGRAVE R
Citation: Ag. Awad et al., PRELIMINARY VALIDATION OF A CONCEPTUAL-MODEL TO ASSESS QUALITY-OF-LIFE IN SCHIZOPHRENIA, Schizophrenia research, 15(1-2), 1995, pp. 213-213
Authors:
HESLEGRAVE RJ
VORUGANTI LNP
AWAD AG
Citation: Rj. Heslegrave et al., NEUROPSYCHIATRIC CORRELATES OF QUALITY-OF-LIFE IN SCHIZOPHRENIA, Schizophrenia research, 15(1-2), 1995, pp. 216-217
Authors:
AWAD AG
HOGAN TP
VORUGANTI LNP
HESLEGRAVE RJ
Citation: Ag. Awad et al., PATIENTS SUBJECTIVE EXPERIENCES ON ANTIPSYCHOTIC MEDICATIONS - IMPLICATIONS FOR OUTCOME AND QUALITY-OF-LIFE, International clinical psychopharmacology, 10, 1995, pp. 123-132
Authors:
VORUGANTI LNP
AWAD AG
Citation: Lnp. Voruganti et Ag. Awad, CLINICAL-EVALUATION OF PSYCHOTROPIC-DRUGS FOR PSYCHIATRIC-DISORDERS, PRINCIPLES AND PROPOSED GUIDELINES, VOL 2 - GROF,P, Journal of psychiatry & neuroscience, 19(2), 1994, pp. 152-152
Authors:
HESLEGRAVE RH
VORUGANTI LNP
AWAD AG
Citation: Rh. Heslegrave et al., AN EVALUATION OF COMPUTERIZED NEUROCOGNITIVE ASSESSMENT OF SCHIZOPHRENIA, Schizophrenia research, 11(2), 1994, pp. 163-163